排序方式: 共有145条查询结果,搜索用时 46 毫秒
101.
102.
Abeer N. Alshukairi Jincun Zhao Maha A. Al-Mozaini Yanqun Wang Ashraf Dada Salim A. Baharoon Sara Alfaraj Waleed A. Ahmed Mushira A. Enani Fatehi E. Elzein Nazik Eltayeb Laila Layqah Aiman El-Saed Husam A. Bahaudden Abdul Haseeb Sherif A. El-Kafrawy Ahmed M. Hassan Najlaa A. Siddiq Ibtihaj Alsharif Isamel Qushmaq Esam I. Azhar Stanley Perlman Ziad A. Memish 《Emerging infectious diseases》2021,27(5):1472
Understanding the immune response to Middle East respiratory syndrome coronavirus (MERS-CoV) is crucial for disease prevention and vaccine development. We studied the antibody responses in 48 human MERS-CoV infection survivors who had variable disease severity in Saudi Arabia. MERS-CoV–specific neutralizing antibodies were detected for 6 years postinfection. 相似文献
103.
Transmission of Middle East Respiratory Syndrome Coronavirus Infections in Healthcare Settings,Abu Dhabi 总被引:1,自引:0,他引:1
Jennifer C. Hunter Duc Nguyen Bashir Aden Zyad Al Bandar Wafa Al Dhaheri Kheir Abu Elkheir Ahmed Khudair Mariam Al Mulla Feda El Saleh Hala Imambaccus Nawal Al Kaabi Farrukh Amin Sheikh Jurgen Sasse Andrew Turner Laila Abdel Wareth Stefan Weber Asma Al Ameri Wesal Abu Amer Negar N. Alami Sudhir Bunga Lia M. Haynes Aron J. Hall Alexander J. Kallen David Kuhar Huong Pham Kimberly Pringle Suxiang Tong Brett L. Whitaker Susan I. Gerber Farida Ismail Al Hosani 《Emerging infectious diseases》2016,22(4):647-656
Middle East respiratory syndrome coronavirus (MERS-CoV) infections sharply increased in the Arabian Peninsula during spring 2014. In Abu Dhabi, United Arab Emirates, these infections occurred primarily among healthcare workers and patients. To identify and describe epidemiologic and clinical characteristics of persons with healthcare-associated infection, we reviewed laboratory-confirmed MERS-CoV cases reported to the Health Authority of Abu Dhabi during January 1, 2013–May 9, 2014. Of 65 case-patients identified with MERS-CoV infection, 27 (42%) had healthcare-associated cases. Epidemiologic and genetic sequencing findings suggest that 3 healthcare clusters of MERS-CoV infection occurred, including 1 that resulted in 20 infected persons in 1 hospital. MERS-CoV in healthcare settings spread predominantly before MERS-CoV infection was diagnosed, underscoring the importance of increasing awareness and infection control measures at first points of entry to healthcare facilities. 相似文献
104.
Francesca Curreli Shahad Ahmed Sofia M. B. Victor Aleksandra Drelich Siva S. Panda Andrea Altieri Alexander V. Kurkin Chien-Te K. Tseng Christopher D. Hillyer Asim K. Debnath 《Viruses》2022,14(1)
We report the discovery of several highly potent small molecules with low-nM potency against severe acute respiratory syndrome coronavirus (SARS-CoV; lowest half-maximal inhibitory concentration (IC50: 13 nM), SARS-CoV-2 (IC50: 23 nM), and Middle East respiratory syndrome coronavirus (MERS-CoV; IC50: 76 nM) in pseudovirus-based assays with excellent selectivity index (SI) values (>5000), demonstrating potential pan-coronavirus inhibitory activities. Some compounds showed 100% inhibition against the cytopathic effects (CPE; IC100) of an authentic SARS-CoV-2 (US_WA-1/2020) variant at 1.25 µM. The most active inhibitors also potently inhibited variants of concern (VOCs), including the UK (B.1.1.7) and South African (B.1.351) variants and the Delta variant (B.1.617.2) originally identified in India in pseudovirus-based assay. Surface plasmon resonance (SPR) analysis with one potent inhibitor confirmed that it binds to the prefusion SARS-CoV-2 spike protein trimer. These small-molecule inhibitors prevented virus-mediated cell–cell fusion. The absorption, distribution, metabolism, and excretion (ADME) data for one of the most active inhibitors, NBCoV1, demonstrated drug-like properties. An in vivo pharmacokinetics (PK) study of NBCoV1 in rats demonstrated an excellent half-life (t1/2) of 11.3 h, a mean resident time (MRT) of 14.2 h, and oral bioavailability. We expect these lead inhibitors to facilitate the further development of preclinical and clinical candidates. 相似文献
105.
《Médecine et maladies infectieuses》2020,50(3):243-251
Since the first case of human infection by the Middle East respiratory syndrome coronavirus (MERS-CoV) in Saudi Arabia in June 2012, more than 2260 cases of confirmed MERS-CoV infection and 803 related deaths have been reported since the 16th of October 2018. The vast majority of these cases (71%) were reported in Saudi Arabia but the epidemic has now spread to 27 countries and has not ceased 6 years later, unlike SARS-CoV that disappeared a little less than 2 years after emerging. Due to the high fatality rate observed in MERS-CoV infected patients (36%), much effort has been put into understanding the origin and pathophysiology of this novel coronavirus to prevent it from becoming endemic in humans. This review focuses in particular on the origin, epidemiology and clinical manifestations of MERS-CoV, as well as the diagnosis and treatment of infected patients. The experience gained over recent years on how to manage the different risks related to this kind of epidemic will be key to being prepared for future outbreaks of communicable disease. 相似文献
106.
Peninah M. Munyua Isaac Ngere Elizabeth Hunsperger Adano Kochi Patrick Amoth Lydia Mwasi Suxiang Tong Athman Mwatondo Natalie Thornburg Marc-Alain Widdowson M. Kariuki Njenga 《Emerging infectious diseases》2021,27(4):1201
Although seroprevalence of Middle East respiratory coronavirus syndrome is high among camels in Africa, researchers have not detected zoonotic transmission in Kenya. We followed a cohort of 262 camel handlers in Kenya during April 2018–March 2020. We report PCR-confirmed Middle East respiratory coronavirus syndrome in 3 asymptomatic handlers. 相似文献
107.
108.
109.
110.
Guo Liya Wang Yuguang Liu Jian Yuan Huaiping Han Xue Huo Jianwei Ma Jiaju Lu Youran Ming Chen Jiao Yiqing 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2020,128(6):423-432
Coronaviruses are a class of RNA viruses that can cause respiratory and intestinal infections in animals and humans. SARS-CoV, MERS-CoV, and a novel coronavirus (SARS-CoV-2 [2019-nCoV]) belong to the family Coronaviridae and the genus Betacoronavirus. At present, the understanding of SARS-CoV-2 is getting deeper and deeper. In order to better prevent and treat SARS-CoV-2, this article compares the infectivity, pathogenicity, and related clinical characteristics of the three human pathogenic coronaviruses, SARS-CoV-2, SARS-CoV, and MERS-CoV to help us further understand the pathogenic characteristics of novel coronaviruses. 相似文献